Matching articles for "flunisolide"
Issue 1725 · March 31, 2025 Free
Treatment of Allergic Rhinitis and Allergic Conjunctivitis

Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2025 Mar 31; 67(1725):49-56 doi:10.58347/tml.2025.1725a
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1725 · March 31, 2025
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)

View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis

Med Lett Drugs Ther. 2025 Mar 31; 67(1725):e58-63 doi:10.58347/tml.2025.1725c
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Issue 1622 · April 19, 2021
Drugs for Allergic Rhinitis and Allergic Conjunctivitis

The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):57-64
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1622 · April 19, 2021
Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)

View the Comparison Table: Some Oral Drugs for Allergic Rhinitis

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):e63-5
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Issue 1622 · April 19, 2021
Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)

View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):e66-71
View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis
Issue 1606 · September 7, 2020
Table: Correct Use of Inhalers for COPD (online only)

View the Table: Correct Use of Inhalers for COPD

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):e150-4
View the Table: Correct Use of Inhalers for COPD
Issue 1528 · August 28, 2017
Drugs for Asthma

The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed here.

Med Lett Drugs Ther. 2017 Aug 28; 59(1528):139-46
The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed here.
Issue 1528 · August 28, 2017
Comparison Table: Some Inhaled Drugs for Treatment of Asthma (online only)

View the Comparison Table: Some Inhaled Drugs for Treatment of Asthma

Med Lett Drugs Ther. 2017 Aug 28; 59(1528):e146-9
View the Comparison Table: Some Inhaled Drugs for Treatment of Asthma
Issue 1528 · August 28, 2017
Comparison Table: Correct Use of Inhalers for Asthma (online only)

View the Comparison Table: Correct Use of Inhalers

Med Lett Drugs Ther. 2017 Aug 28; 59(1528):e150-2
View the Comparison Table: Correct Use of Inhalers
Issue 1520 · May 8, 2017
Drugs for Allergic Disorders

Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation…

Med Lett Drugs Ther. 2017 May 8; 59(1520):71-82
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation H 1 -antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Issue 1520 · May 8, 2017
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)

View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis

Med Lett Drugs Ther. 2017 May 8; 59(1520):e85-90
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Issue 1518 · April 10, 2017
Drugs for COPD

The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for…

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):57-62
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for treatment of COPD have been published in recent years.
Issue 1518 · April 10, 2017
Comparison Table: Some Inhaled Corticosteroids for COPD (online only)

View the Comparison Table: Some Inhaled Corticosteroids for COPD

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):e66
View the Comparison Table: Some Inhaled Corticosteroids for COPD
Issue 1518 · April 10, 2017
Table: Correct Use of Inhalers for COPD (online only)

View the Table: Correct Use of Inhalers for COPD

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):e67-71
View the Table: Correct Use of Inhalers for COPD
Issue 1469 · May 25, 2015
Fluticasone Furoate (Arnuity Ellipta) for Asthma

The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone…

Med Lett Drugs Ther. 2015 May 25; 57(1469):76-9
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta 2 -agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.
Issue 132 · August 1, 2013
Drugs for Asthma and COPD

INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young children…

Treat Guidel Med Lett. 2013 Aug; 11(132):75-86
INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young children and the elderly, use MDIs effectively. VHCs have one-way valves that prevent the patient from exhaling into the device, minimizing the need for coordinated actuation and inhalation. Spacers are tubes or chambers placed between the canister and a face mask or mouthpiece, which also avoids the need to coordinate actuation and inhalation. Both VHCs and spacers retain the larger particles emitted from the MDI, decreasing their deposition in the oropharynx and leading to a higher proportion of small respirable particles being inhaled.
Issue 129 · May 1, 2013
Drugs for Allergic Disorders

The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.

Treat Guidel Med Lett. 2013 May; 11(129):43-52
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Issue 1402 · October 29, 2012
Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis

The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and…

Med Lett Drugs Ther. 2012 Oct 29; 54(1402):85-7
The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H 1 -antihistamine and a corticosteroid.
Issue 114 · February 1, 2012
Drugs for Asthma

Inhalation is the preferred route of delivery for most asthma drugs. Chlorofluorocarbons (CFCs), which have ozone-depleting properties, are being phased out as propellants in metered-dose inhalers.…

Treat Guidel Med Lett. 2012 Feb; 10(114):11-8
Inhalation is the preferred route of delivery for most asthma drugs. Chlorofluorocarbons (CFCs), which have ozone-depleting properties, are being phased out as propellants in metered-dose inhalers. Non-chlorinated hydrofluoroalkane (HFA) propellants, which do not deplete the ozone layer, are being used instead.
Issue 99 · November 1, 2010
Drugs for Chronic Obstructive Pulmonary Disease

The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such…

Treat Guidel Med Lett. 2010 Nov; 8(99):83-8
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such as acute exacerbations. Other guidelines for treatment of this condition have been published or updated in recent years.
Issue 76 · December 1, 2008
Drugs for Asthma

No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become…

Treat Guidel Med Lett. 2008 Dec; 6(76):83-90
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become available.
Issue 1295 · September 22, 2008
Ciclesonide (Alvesco) - A New Inhaled Corticosteroid for Asthma

The FDA has approved the marketing of the corticosteroid ciclesonide ( Alvesco - Sepracor) in a hydrofluoroalkane (HFA) metered-dose inhaler formulation for maintenance treatment of asthma in patients >12…

Med Lett Drugs Ther. 2008 Sep 22; 50(1295):75-6
The FDA has approved the marketing of the corticosteroid ciclesonide ( Alvesco - Sepracor) in a hydrofluoroalkane (HFA) metered-dose inhaler formulation for maintenance treatment of asthma in patients >12 years old. Ciclesonide is also available in the US as a nasal spray for allergic rhinitis ( Omnaris ), and has been available for asthma in Europe since 2003.
Issue 1285 · May 5, 2008
Ciclesonide (Omnaris) for Allergic Rhinitis

Ciclesonide ( Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial…

Med Lett Drugs Ther. 2008 May 5; 50(1285):33-4
Ciclesonide ( Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter
Issue 1279 · February 11, 2008
Budesonide/Formoterol (Symbicort) for Asthma

A combination of the corticosteroid budesonide and the long-acting beta 2 -agonist formoterol ( Symbicort - AstraZeneca) has become available in a metered dose inhaler for long-term maintenance treatment of…

Med Lett Drugs Ther. 2008 Feb 11; 50(1279):9-11
A combination of the corticosteroid budesonide and the long-acting beta 2 -agonist formoterol ( Symbicort - AstraZeneca) has become available in a metered dose inhaler for long-term maintenance treatment of asthma in patients ≥ 12 years old. A combination product that contains fluticasone propionate and salmeterol (Advair) is already available for this indication in the US. Neither one of these combinations is approved for acute treatment of asthma symptoms. A dry powder inhaler formulation of Symbicort has been available in Europe and Canada for several years.
Issue 1273 · November 5, 2007
Fluticasone Furoate (Veramyst) for Allergic Rhinitis

Fluticasone furoate nasal spray ( Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone…

Med Lett Drugs Ther. 2007 Nov 5; 49(1273):90-2
Fluticasone furoate nasal spray ( Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone propionate nasal spray ( Flonase , and others), which is now available generically.
Issue 63 · November 1, 2007
Drugs for Chronic Obstructive Pulmonary Disease

The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such…

Treat Guidel Med Lett. 2007 Nov; 5(63):95-100
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such as acute exacerbations and cor pulmonale. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines developed by the World Health Organization and the National Heart, Lung and Blood Institute were updated in 2006. The American Thoracic Society and the European Respiratory Society jointly developed guidelines for COPD in 2004.
Issue 60 · August 1, 2007
Drugs for Allergic Disorders

Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in…

Treat Guidel Med Lett. 2007 Aug; 5(60):71-80
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in industrialized countries. Pharmacologic treatment of these disorders continues to improve in efficacy and safety. In addition to using drugs to prevent and control the symptoms of their allergic diseases, patients should also be instructed to avoid, if possible, specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Issue 1223 · December 5, 2005
Mometasone (Asmanex Twisthaler) for Asthma

The FDA has approved marketing of the corticosteroid mometasone furoate in an orally inhaled dry powder formulation ( Asmanex Twisthaler - Schering-Plough) for maintenance treatment of asthma in patients at…

Med Lett Drugs Ther. 2005 Dec 5; 47(1223):98-9
The FDA has approved marketing of the corticosteroid mometasone furoate in an orally inhaled dry powder formulation ( Asmanex Twisthaler - Schering-Plough) for maintenance treatment of asthma in patients at least 12 years old. Mometasone is also available as a mid-potency topical corticosteroid cream ( Elocon ) and as an intranasal spray ( Nasonex ) for treatment of allergic rhinitis.
Issue 1220 · October 24, 2005
Montelukast (Singulair) for Perennial Allergic Rhinitis

Montelukast ( Singulair - Merck) is an oral cysteinyl leukotriene D 4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic…

Med Lett Drugs Ther. 2005 Oct 24; 47(1220):87-4
Montelukast ( Singulair - Merck) is an oral cysteinyl leukotriene D 4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic rhinitis and recently for use in perennial allergic rhinitis in adults and children ≥ 6 months old. Intranasal corticosteroids have generally been considered the most effective drugs available for prevention and treatment of allergic rhinitis.
Issue 33 · May 1, 2005
Drugs for Asthma

Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other…

Treat Guidel Med Lett. 2005 May; 3(33):33-8
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other than for exercise-induced bronchospasm, indicates a need for anti-inflammatory treatment. Inhaled corticosteroids are the most effective anti-inflammatory medication; leukotriene modifiers are less effective alternatives. If regular use of an inhaled corticosteroid in a low dose does not prevent symptoms, a long-acting beta2-agonist should be added; addition of a second drug is more effective than raising the dose of the inhaled steroid. A leukotriene modifier can also be used as the second drug. Omalizumab may be considered as adjunctive therapy for patients more than 12 years old who have allergic asthma not controlled by other drugs. A short course of oral corticosteroids may be useful for acute exacerbations. Treatment of acute severe asthma as a medical emergency is not included here; it has been reviewed elsewhere (ER McFadden Jr, Am J Respir Crit Care Med 2003; 168:740) .
Issue 15 · November 1, 2003
Drugs for Allergic Disorders

Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence…

Treat Guidel Med Lett. 2003 Nov; 1(15):93-100
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence during the past 30 years and are now epidemic worldwide, especially in industrialized countries. Many safe and effective drugs are currently available for prevention and relief of symptoms in these disorders, but pharmacological treatment alone may not be sufficient. Patients should also be instructed to avoid specific allergens or environmental conditions that trigger their symptoms. Allergen-specific immunotherapy, parenteral administration of gradually increasing doses of the allergen ("allergy shots"), has been effective in allergic rhinitis, allergic conjunctivitis and allergic asthma, and also in prevention of anaphylaxis triggered by stings from bees, yellow jackets, hornets and wasps. It has not been effective in food allergy, atopic dermatitis or urticaria.
Issue 1152 · March 17, 2003
Montelukast (Singulair) for Allergic Rhinitis

Montelukast ( Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma ( Treatment Guidelines from The Medical Letter 2002; 1:11 ), has been approved by the FDA for treatment of…

Med Lett Drugs Ther. 2003 Mar 17; 45(1152):21-2
Montelukast ( Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma ( Treatment Guidelines from The Medical Letter 2002; 1:11 ), has been approved by the FDA for treatment of seasonal allergic rhinitis in adults and children more than 2 years old.
Issue 2 · October 1, 2002
Drugs for Asthma

New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment…

Treat Guidel Med Lett. 2002 Oct; 0(2):7-12
New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment of asthma in the emergency department or hospital is not addressed here. More information on the diagnosis and treatment of asthma is available from Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma (Bethesda:NIH, 1997 and 2002 update; www.nhlbi.nih.gov ).
Issue 1102 · April 16, 2001
A Combination of Fluticasone and Salmeterol For Asthma

Fluticasone propionate, an inhaled corticosteroid, and salmeterol xinafoate, a long-acting beta2-adrenergic agonist, are now available together in a dry-powder inhaler for maintenance treatment of patients…

Med Lett Drugs Ther. 2001 Apr 16; 43(1102):31-3
Fluticasone propionate, an inhaled corticosteroid, and salmeterol xinafoate, a long-acting beta2-adrenergic agonist, are now available together in a dry-powder inhaler for maintenance treatment of patients with asthma. The new combination is not recommended for treatment of acute bronchospasm or for treatment of children less than 12 years old.
Issue 1073 · March 6, 2000
Drugs for Asthma

Asthma is a chronic inflammatory disorder of the airways; inflammation caused by allergens, viral respiratory infections or other stimuli leads to bronchial hyperresponsiveness and obstruction of airflow.…

Med Lett Drugs Ther. 2000 Mar 6; 42(1073):19-24
Asthma is a chronic inflammatory disorder of the airways; inflammation caused by allergens, viral respiratory infections or other stimuli leads to bronchial hyperresponsiveness and obstruction of airflow. Anti-inflammatory drugs, particularly inhaled corticosteroids, are central to its management.
Issue 1046 · February 12, 1999
Mometasone Furoate Nasal Spray for Allergic Rhinitis

An intranasal spray formulation of the topical corticosteroid mometasone furoate, marketed for treatment of seasonal and perennial allergic rhinitis, has been advertised on television directly to the public.

Med Lett Drugs Ther. 1999 Feb 12; 41(1046):16-7
An intranasal spray formulation of the topical corticosteroid mometasone furoate, marketed for treatment of seasonal and perennial allergic rhinitis, has been advertised on television directly to the public.
Issue 1044 · January 15, 1999
Drugs for Asthma

Asthma is a chronic inflammatory disorder, with inflammation caused by allergens or other stimuli leading to bronchial hyperresponsiveness and obstruction of airflow.

Med Lett Drugs Ther. 1999 Jan 15; 41(1044):5-10
Asthma is a chronic inflammatory disorder, with inflammation caused by allergens or other stimuli leading to bronchial hyperresponsiveness and obstruction of airflow.
Issue 1031 · July 17, 1998
Montelukast for Persistent Asthma

Montelukast sodium ( Singulair - Merck), a leukotriene receptor antagonist, has been approved by the US Food and Drug Administration (FDA) for oral prophylaxis and chronic treatment of asthma in adults and…

Med Lett Drugs Ther. 1998 Jul 17; 40(1031):71-3
Montelukast sodium ( Singulair - Merck), a leukotriene receptor antagonist, has been approved by the US Food and Drug Administration (FDA) for oral prophylaxis and chronic treatment of asthma in adults and children at least 6 years old. It is the third 'leukotriene modifier' to become available in the USA; zafirlukast ( Accolate - Medical Letter, 38:111, 1996) and zileuton ( Zyflo - Medical Letter, 39:18, 1997) were marketed previously. Neither zafirlukast nor zileuton has been approved by the FDA for use in children less than 12 years old. Leukotriene modifiers are not recommended for treatment of an acute asthma attack ( Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma , Bethesda: NIH, 1997; www.nhlbi.NIH.gov/nhlbi/lung/ asthma/prof/asthgdln.htm).
Issue 1018 · January 16, 1998
Budesonide Turbuhaler for Asthma

The FDA has approved marketing of the corticosteroid budesonide in an oral inhalatoin powder formulation ( Pulmicort Turbuhaler - Astra) for maintenance treatment of asthma in adults and children at least six…

Med Lett Drugs Ther. 1998 Jan 16; 40(1018):15-6
The FDA has approved marketing of the corticosteroid budesonide in an oral inhalatoin powder formulation ( Pulmicort Turbuhaler - Astra) for maintenance treatment of asthma in adults and children at least six years old. Budesonide has been available in the USA as an intranasal spray (Rhinocort) for treatment of allergic rhinitis since 1994 and has been used for inhalation treatment of asthma in Canada and Europe for ten years.
Issue 1000 · May 9, 1997
Azelastine Nasal Spray for Allergic Rhinitis

Azelastine hydrochloride, a histamine-H1 receptor antagonist, has been marketed as a 0.1% nasal spray ( Astelin - Wallace) for treatment of seasonal allergic rhinitis. Corticosteroid and cromolyn sodium nasal…

Med Lett Drugs Ther. 1997 May 9; 39(1000):45-7
Azelastine hydrochloride, a histamine-H1 receptor antagonist, has been marketed as a 0.1% nasal spray ( Astelin - Wallace) for treatment of seasonal allergic rhinitis. Corticosteroid and cromolyn sodium nasal sprays are also available for this indication (Medical Letter, 37:5, 1995). Cromolyn sodium ( Nasalcrom ) has now been approved for over-the-counter use.
Issue 990 · December 20, 1996
Zafirlukast for Asthma

Zafirlukast (za fir loo kast; Accolate - Zeneca), the first leukotriene receptor anta-gonist approved by the US Food and Drug Administration, is now being heavily promoted for oral maintenance treatment of…

Med Lett Drugs Ther. 1996 Dec 20; 38(990):111-2
Zafirlukast (za fir loo kast; Accolate - Zeneca), the first leukotriene receptor anta-gonist approved by the US Food and Drug Administration, is now being heavily promoted for oral maintenance treatment of chronic asthma in patients more than 12 years old. It is not recommended for treatment of acute asthma.
Issue 983 · September 13, 1996
Fluticasone Propionate for Chronic Asthma

An inhalation aerosol formulation of the corticosteroid fluticasone propionate ( Flovent -Glaxo Wellcome) has been approved by the US Food and Drug Administration for maintenance treatment of asthma.

Med Lett Drugs Ther. 1996 Sep 13; 38(983):83-4
An inhalation aerosol formulation of the corticosteroid fluticasone propionate ( Flovent -Glaxo Wellcome) has been approved by the US Food and Drug Administration for maintenance treatment of asthma.
Issue 940 · January 20, 1995
Fluticasone Propionate Nasal Spray for Allergic Rhinitis

An intranasal spray formulation of the corticosteroid fluticasone propionate (floo tik a sone; Flonase - Allen & Hanburys) has been approved by the US Food and Drug Administration for treatment of seasonal and…

Med Lett Drugs Ther. 1995 Jan 20; 37(940):5-6
An intranasal spray formulation of the corticosteroid fluticasone propionate (floo tik a sone; Flonase - Allen & Hanburys) has been approved by the US Food and Drug Administration for treatment of seasonal and perennial allergic rhinitis in adults and children more than 12 years old.
Issue 926 · July 8, 1994
Intranasa Budesonide for Allergic Rhinitis

An intranasal formulation of the corticosteroid budesonide ( Rhinocort Nasal Inhaler - Astra) was recently approved by the US Food and Drug Administration for treatment of seasonal or perennial allergic…

Med Lett Drugs Ther. 1994 Jul 8; 36(926):63-4
An intranasal formulation of the corticosteroid budesonide ( Rhinocort Nasal Inhaler - Astra) was recently approved by the US Food and Drug Administration for treatment of seasonal or perennial allergic rhinitis in adults and children and nonallergic perennial rhinitis in adults. Budesonide has been available in Canada and Europe for several years for inhalation treatment of both allergic rhinitis and asthma.
Issue 921 · April 29, 1994
Salmeterol

Salmeterol xinafoate ( Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of…

Med Lett Drugs Ther. 1994 Apr 29; 36(921):37-8
Salmeterol xinafoate ( Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of asthma, with or without concurrent use of inhaled corticosteroids. Salmeterol is not recommended for acute treatment of bronchospasm.
Issue 859 · December 13, 1991
Intranasal Triamcinolone For Allergic Rhinitis

An intranasal formulation of the corticosteroid triamcinolone ( Nasacort - Rh ne- Poulenc Rorer) was recently approved by the US Food and Drug Administration for once-daily treatment of seasonal and perennial…

Med Lett Drugs Ther. 1991 Dec 13; 33(859):116-7
An intranasal formulation of the corticosteroid triamcinolone ( Nasacort - Rh ne- Poulenc Rorer) was recently approved by the US Food and Drug Administration for once-daily treatment of seasonal and perennial allergic rhinitis.